The faculty for this activity are listed below:

The faculty for this activity are listed below:
Nader Hanna, MD (Planner)

Seth Felder, MD (Moderator/Planner)

Patrick Sullivan, MD (Faculty)

Jeremiah Deneve, DO (Faculty)

Ashwin Somasundaram, MD (Faculty)

Noam VanderWalde, MD (Faculty)

Aarti K. Sekhar, MD (Faculty) 

This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with colorectal cancer.

At the conclusion of this activity, participants should be able to:

•  Recognize the distinction between regional colorectal cancer lymph node metastasis compared to retroperitoneal (non-regional metastasis) on imaging
•  Understand  treatment considerations directed at Stage 4 colorectal cancer retroperitoneal lymph node disease, including systemic vs local strategies (operative resection; radiation)
• Summarize the management for colorectal cancer metastatic to retroperitoneal lymph node(s) presenting at time of diagnosis (synchronous) or metachronously, including isolated nodal disease vs oligometastatic.

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Surgical Oncology designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity consists of educational content and evaluation. Learners must view the activity content and complete the post-activity evaluation in order to earn credit. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.

The estimated time to complete this entire activity is 1 hour.

Release Date

        September 16, 2024

CME Expiration Date

          September 16, 2025

As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

All identified conflicts of interest must be mitigated, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.

All identified conflicts of interests have been mitigated.

Faculty
Nader Hanna, MD, has disclosed no financial relationships.

Seth Felder, MD, has disclosed no financial relationships.

Jeremiah Deneve, DO, has disclosed no financial relationships.

Patrick Sullivan MD, has disclosed no financial relationships.

Noam VanderWalde, MD, MS, has disclosed has disclosed the following financial relationships - Daiichi Sankyo.

Ashwin Somasundaram MD, has disclosed no financial relationships.

Aarti Sekhar, MD, has disclosed no financial relationships.

Planners, Reviewers, and Staff

Ali Raza, MD, CME Committee Reviewer, has disclosed no financial relationships.

Patti Stella, CAE, CHCP, Society of Surgical Oncology, has disclosed the following financial relationships - Horizon Therapeutics, SODR Biotech (XBI).

Meagan Gilliland-Johnson, Society of Surgical Oncology, has disclosed no financial relationships.

Devin Winkler, Society of Surgical Oncology, has disclosed no financial relationships.

The primary purpose of the Society of Surgical Oncology's internet live course is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site: https://www.surgonc.org/about-sso/privacy-policy/.

System requirements for this activity can be found by clicking the Help button. For technical support, please contact us at expertED@surgonc.org